Get the Stockscreener App
17.33
1.53%
-0.27
After Hours:
17.38
0.05
+0.29%
Pulse Biosciences Inc stock is traded at $17.33, with a volume of 170.70K.
It is down -1.53% in the last 24 hours and up +19.35% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$17.60
Open:
$17.92
24h Volume:
170.70K
Relative Volume:
0.92
Market Cap:
$1.17B
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-16.50
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
-10.90%
1M Performance:
+19.35%
6M Performance:
+8.04%
1Y Performance:
+1.46%
1-Day Range:
$16.83
$18.09
1-Week Range:
$16.83
$20.20
52-Week Range:
$13.77
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
17.33 | 1.18B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
435.73 | 154.00B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.66 | 53.47B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
273.01 | 39.70B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
72.60 | 35.62B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
262.47 | 18.82B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Using fundamentals and technicals on Pulse Biosciences Inc.Portfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Using data filters to optimize entry into Pulse Biosciences Inc.Market Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
Visualizing Pulse Biosciences Inc. stock with heatmapsBear Alert & Detailed Earnings Play Strategies - newser.com
Sector ETF performance correlation with Pulse Biosciences Inc.Portfolio Profit Report & Technical Entry and Exit Alerts - newser.com
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse - Yahoo Finance
Why hedge funds are buying Pulse Biosciences Inc. stockJuly 2025 Short Interest & High Conviction Trade Alerts - newser.com
Tick level data insight on Pulse Biosciences Inc. volatility2025 Buyback Activity & Daily Growth Stock Tips - newser.com
Will Pulse Biosciences Inc. stock beat EPS estimates2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Pulse Biosciences (PLSE): Assessing Valuation After Recent Share Price Swings - Yahoo Finance
Pulse Biosciences’ Npulse successful in epicardial PFA - BioWorld MedTech
Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing
Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com Nigeria
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire
Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm
Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm
Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com
Pulse Biosciences Expands Equity Incentive Plan - MSN
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey
What drives Pulse Biosciences Inc 6L8 stock priceStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
First Procedures Conducted in PRECISE Benign Thyroid Nodule Study - Medical Product Outsourcing
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
2.84%
3.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):